Get Free Trial
News & Analysis
On The Fly
About The Fly
Instant updates and real-time market news.
CME Group management to meet with Evercore ISI
Meeting to be held in Texas on October 4 hosted by Evercore ISI.
On The Fly: Top five analyst initiations
Catch up on the today's top analyst initiations with this list compiled by The Fly: 1. IntercontinentalExchange (ICE) initiated with a Buy at Sterne Agee CRT by analyst Jason Weaver, who put a $300 price target on shares. The firm has a positive view of what it sees as the company's "leading position and growth trajectory in energy, equity, and fixed income trading and clearing." The firm adds that the company's revenue mix is less volatile than its peers, while synergies and cost controls have made the company more profitable. Weaver also initiated Nasdaq (NDAQ) with a Buy rating and $76 price target, CME Group (CME) with a Neutral rating and $90 price target and CBOE Holdings (CBOE) with an Underperform rating and $56 price target. 2. Akari Therapeutics (AKTX) initiated with a Buy rat Canaccord. The firm set a $33 price target on shares and cited expectations for FDA product approvals and a level of underappreciation by investors for its shares. 3. Ralph Lauren (RL) initiated with a Buy and $115 price target by BB&T analyst Corinna Freedman, who believes Ralph Lauren will be successful in its turnaround and gain relevancy among a new younger demographic due to its strong vertical global brand house with a powerful heritage and sees significant category opportunities remaining in Women's and Accessories. Additionally, Freedman said International growth opportunities remain and Club Monaco repositioning is underappreciated. 4. Johnson & Johnson (JNJ) initiated with a Sell at Standpoint Research and $94 target. 5. PACCAR (PCAR) initiated with a Hold at Argus. The firm said it expects challenging industry conditions to pressure earnings through 2017. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage,
CME Group price target raised to $118 from $112 at Jefferies
Jefferies analyst Daniel Fannon raised his price target for CME Group to $118 after traveling with management. The analyst says the diversity of CME's growth continues and he keeps a Buy rating on the shares.
CME Group price target raised to $116 from $106 at JPMorgan
JPMorgan analyst Kenneth Worthington raised his price target for CME Group to $116 saying the company's product mix benefits from the current market environment. The analyst sees further share upside and keeps an Overweight rating on CME.
CBOE 'likely in the cross-hairs' of bigger peers, says RBC Capital
RBC Capital analyst Andrew Bond said he thinks the strategic risk of a deal whereby CBOE (CBOE) buys Bats Global Markets (BATS), as it has been reported to be in talks to do, outweighs the potential reward. However, he also believe CBOE's relatively small size, limited regulatory risk, clean balance sheet, and strong organic growth make it an attractive target for its largest exchange peers, such as IntercontinentalExchange (ICE) and CME Group (CME). A combined CBOE/BATS would be more difficult to acquire, so if CBOE is to be acquired, "the time is now," added Bond.
TODAY'S FREE FLY STORIES